UCB has opened an unusual development path for CIMZIA, or certolizumab pegol, a tumour necrosis factor inhibitor already widely used in inflammatory diseases. The United States Food and Drug Administration has granted Breakthrough Therapy Designation for prevention of placenta-mediated adverse pregnancy outcomes in high-risk pregnant women with antiphospholipid syndrome who are positive for lupus anticoagulant, used in addition to standard anticoagulant therapy. There are currently no FDA-approved treatments specifically indicated to prevent these pregnancy complications in APS.
The designation is supported by the Phase 2 IMPACT study, which evaluated certolizumab alongside low molecular weight heparin and low-dose aspirin. Among 45 evaluable pregnancies in the modified intention-to-treat population, the primary composite adverse pregnancy outcome occurred in 20%, compared with an expected rate of roughly 40% derived from prospectively observed historical controls with similarly high-risk APS. Median gestational age at delivery was 36.5 weeks and neonatal survival to hospital discharge reached 93%.
Why does obstetric antiphospholipid syndrome remain difficult despite anticoagulation?
Antiphospholipid syndrome is an autoimmune condition associated with pathogenic antibodies that increase thrombotic risk. During pregnancy, APS can contribute to recurrent fetal loss, pre-eclampsia, placental insufficiency, fetal growth restriction, preterm birth and stillbirth.
Standard obstetric management commonly combines low-dose aspirin with heparin or low molecular weight heparin. That strategy addresses coagulation and improves outcomes for many patients, yet women with persistent lupus anticoagulant and prior severe obstetric or thrombotic events can remain at substantial risk even when they receive standard treatment.
That residual risk suggests thrombosis may not be the complete disease mechanism. Inflammation and abnormal placental development are increasingly implicated in APS pregnancy complications, creating a rationale for therapies that act on immune signalling as well as coagulation.
Why target TNF during pregnancy?
Tumour necrosis factor alpha is a major inflammatory cytokine and has been implicated in placental dysfunction in preclinical models of antiphospholipid antibody-mediated pregnancy loss. The IMPACT investigators therefore tested whether TNF blockade could protect placental function when added to conventional anticoagulant therapy.
Certolizumab is particularly suited to this question because its molecular design results in little or no active transport across the placenta compared with many conventional IgG antibodies. That pregnancy pharmacology is already relevant to its use in women with inflammatory diseases and provides a rationale for studying the medicine specifically in maternal-fetal therapy.
The strategy is conceptually different from simply intensifying anticoagulation. Rather than asking whether more powerful clot prevention can reduce complications, IMPACT asks whether inflammatory placental injury can be interrupted upstream.
How persuasive are the IMPACT results?
The primary composite included fetal death at or beyond 10 weeks, severe pre-eclampsia or placental insufficiency requiring delivery before 34 weeks. Nine of 45 patients experienced the endpoint, or 20%, meeting the study’s prespecified criterion for efficacy relative to historical expectations.
The absence of a randomized concurrent control is the most important limitation. Historical comparison can be influenced by differences in patient selection, supportive care, clinical practice and unmeasured characteristics. A 20% event rate therefore cannot be interpreted as definitive proof that certolizumab halves risk in the same way a randomized trial could establish.
Still, additional within-patient analyses are provocative. Among 24 participants whose previous pregnancy treated with low molecular weight heparin and aspirin progressed beyond 10 weeks, adverse pregnancy outcomes occurred in 79% of prior pregnancies compared with 21% during the subsequent certolizumab-treated pregnancy. Live births surviving to discharge increased from 33% in those prior pregnancies to 83% with certolizumab treatment.
Why is lupus anticoagulant positivity central to the programme?
Not every patient with antiphospholipid antibodies has the same pregnancy risk. Persistent lupus anticoagulant is associated with particularly poor obstetric outcomes and was deliberately used to identify the high-risk population in IMPACT.
That enrichment strategy resembles precision medicine in other therapeutic areas. Instead of testing an intervention across every patient who carries any antiphospholipid antibody, researchers focused on women with a biomarker and clinical history suggesting substantial residual risk despite accepted therapy.
Regulatory development may depend on preserving that precision. A broad APS label would require evidence across a much more heterogeneous population, while a targeted indication could concentrate treatment on women most likely to derive benefit.
How important is the safety question when treating pregnant patients?
Safety standards are exceptionally demanding in pregnancy because both the mother and developing fetus must be considered. Investigational treatments for maternal disease can face a higher practical evidentiary burden even when the underlying condition carries severe risk.
In the published IMPACT analysis, there were no serious infections and no new cases or severe flares of lupus. Neonatal survival to hospital discharge was 93%. Those findings are reassuring but come from a relatively small Phase 2 population and cannot exclude uncommon maternal or fetal risks.
Certolizumab does have an advantage in that it is already an established medicine with extensive experience in other immune-mediated diseases, including use among women of childbearing age. UCB has separately studied drug exposure during pregnancy through programmes such as CHERISH.
What does Breakthrough Therapy Designation actually change?
The designation is not approval. It means the FDA believes preliminary clinical evidence indicates that the therapy may offer substantial improvement over available treatment for a serious condition and provides a framework for closer regulatory interaction and potentially expedited development.
For UCB, the designation can help shape the next clinical programme before a large pivotal trial is completed. Trial design will be particularly important because randomized studies in high-risk pregnancy require careful ethical consideration, endpoint selection and specialist recruitment.
The key regulatory question is likely to be what evidence is sufficient to move from suggestive historical comparisons to a treatment claim. A future controlled study may need to establish reduction in severe placental complications without creating unacceptable infection or pregnancy risks.
Could an APS approval extend the commercial life of CIMZIA?
CIMZIA is already an established product across Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis and plaque psoriasis. An obstetric APS indication would therefore represent repurposing of a mature immunology asset rather than launch of a new molecule.
The addressable population is small relative to mainstream autoimmune diseases, but orphan-like indications can carry strategic importance because they diversify use, extend physician familiarity and generate additional value from well-characterized medicines.
More importantly, an approval could create a new therapeutic category. Obstetric APS has historically been managed primarily through anticoagulant and antiplatelet approaches. Demonstrating that targeted immunomodulation improves outcomes would change the biological framework through which some high-risk pregnancies are treated.
Could the concept extend beyond APS?
Placental inflammation contributes to several pregnancy complications, but that does not mean TNF blockade should be assumed effective in conditions beyond APS. The biology, patient population and risk-benefit profile must be demonstrated separately.
The IMPACT investigators have nevertheless argued that their findings justify research into whether TNF blockade might prevent placenta-mediated outcomes in other carefully selected high-risk populations.
That possibility makes this programme scientifically unusual. Many pharmaceutical innovations in pregnancy involve adapting dosing or gathering safety data for drugs already needed to treat maternal illness. UCB is instead evaluating an immunologic therapy specifically to prevent a pregnancy complication.
The breakthrough designation therefore reflects more than another label-extension opportunity. It tests whether a mature biologic can redefine treatment in a condition where standard care has focused on clotting for decades. If a randomized programme confirms IMPACT, CIMZIA could establish the principle that controlling placental inflammation is an essential part of protecting certain APS pregnancies, not merely an experimental add-on.
